top of page

GLP-1 Medications and Obesity-Related Cancer Risk: What Researchers Are Learning

Writer: Women's Cancer Research Foundation
Women's Cancer Research Foundation
11 minutes ago
2 min read
Graphic featuring Bram Goldstein, Ph.D., for “A Clinical Perspective: GLP-1 Medications and Obesity-Related Cancer Risk—What Researchers Are Learning.”

Obesity is associated with an increased risk of several cancers, including endometrial cancer. As GLP-1 receptor agonists become more widely used for weight management, researchers are beginning to examine whether their effects may extend to the risk of developing obesity-related cancers.


A recent observational study compared cancer incidence among adults with obesity but without diabetes who used GLP-1RAs and those who received diet or exercise counseling. Bram Goldstein, Ph.D., President and Senior Clinical Fellow of the Women’s Cancer Research Foundation, provides clinical context on the findings.


As obesity rates continue to rise, so, too, have deaths from obesity-related cancers, such as uterine and colon cancer, with age-adjusted mortality rates tripling between 1999 and 2020.


A new study from Annals of Oncology examined the association between developing an obesity-related cancer and glucagon-like peptide-1 receptor agonists (GLP-1RAs) use in obese people without diabetes. The trial compared people who received two or more prescriptions of a GLP-1RA with people who received diet or exercise counselling to manage their weight. The incidence of obesity-related cancers was monitored for two years.


The study reported that among GLP-1RA users, a 58% reduction was found in the incidence of endometrial cancer, which is the most common gynecologic cancer and very closely linked to obesity. The risk of developing any of 13 obesity-associated cancers was 41% lower in people taking GLP-1RAs compared to people managing their obesity with diet and exercise alone.


Weight loss probably played a key role in the association between GLP-1RA use and reduced cancer risk by improving metabolic health; however, several strands of evidence suggest that anti-cancer effects of GLP-1RAs may extend beyond their direct impacts on obesity. For example, GLP-1RAs are reportedly present on cells of obesity-related cancers such as endometrial cancer, indicative of a biologically plausible anti-cancer effect.


Exploratory analyses of subgroups in the study found that the association between weight-loss drugs and a reduction in cancer risk for men was nearly 70%, much higher than for women. Women have a harder time staying on GLP-1RA medication due to a higher prevalence of gastrointestinal side effects from the drugs, which may explain the difference.


Why This Cancer Research Matters

The relationship between obesity, metabolic health, and cancer risk is complex. Research examining GLP-1RAs may help scientists better understand whether these medications could influence the development of obesity-associated cancers, including endometrial cancer.


These findings show an association; they do not establish that GLP-1RAs prevent cancer. Because the study was observational and examined short-term cancer incidence over two years, longer-term research is needed to better understand the relationship and determine whether any effects extend beyond weight loss.



Medical note: This article is intended for educational purposes only and does not provide medical advice, diagnosis, or individualized screening or treatment recommendations. Please consult a qualified healthcare professional about personal health concerns.

Comments


FORMERLY KNOWN AS THE NANCY YEARY WOMEN'S CANCER RESEARCH FOUNDATION
IN MEMORY OF NANCY AND BOB YEARY

ABOUT US 

Since 1985, the physicians and researchers at the WCRF have been at the forefront of pioneering clinical research, aimed at enhancing cure rates among women diagnosed with breast, ovarian, uterine, and cervical cancers. WCRF actively engages in designing, conducting, and disseminating groundbreaking research focused on cutting-edge medical treatments.


Furthermore, WCRF serves as a vital hub for both foundational and applied research, as well as education, pertaining to the latest advancements in the treatment of breast and gynecologic cancers. In addition to conducting and publishing original research, the WCRF, provides valuable clinical information to physicians and patients alike.
 

 

Subscribe to Our Newsletter

Thanks for submitting!

CONTACT 

T: 949-642-5165

F: 949-646-7157

​

​

699 Diamond Street
Laguna Beach, CA 92651

  • Womens Cancer Research Foundation on X
  • LinkedIn
  • Facebook
  • YouTube
  • Instagram
Wpmen's Cancer Research Foundation

© 2026 Women's Cancer Research Foundation All rights reserved.

Website design by Tribe of Digital Natives

bottom of page